LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Zai Lab Ltd ADR

Cerrado

SectorSanidad

30.12 -3.55

Resumen

Variación precio

24h

Actual

Mínimo

30.02

Máximo

30.45

Métricas clave

By Trading Economics

Ingresos

33M

-48M

Ventas

-2.6M

106M

BPA

-0.45

Margen de beneficios

-45.487

Empleados

1,869

EBITDA

19M

-56M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+109.52% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

17M

3.4B

Apertura anterior

33.67

Cierre anterior

30.12

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

50 / 381 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Zai Lab Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 may 2025, 10:30 UTC

Principales Noticias

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 may 2025, 06:30 UTC

Ganancias

5 Things We've Learned From Retail Earnings -- Barrons.com

31 may 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

30 may 2025, 23:51 UTC

Adquisiciones, fusiones, absorciones

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 may 2025, 21:30 UTC

Principales Noticias

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 may 2025, 21:15 UTC

Principales Noticias

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 may 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

30 may 2025, 20:44 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 may 2025, 20:24 UTC

Principales Noticias

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 may 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

30 may 2025, 19:44 UTC

Charlas de Mercado

Gold Breaks 4-Month Winning Streak -- Market Talk

30 may 2025, 19:38 UTC

Charlas de Mercado

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 may 2025, 19:29 UTC

Ganancias
Adquisiciones, fusiones, absorciones

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 may 2025, 19:14 UTC

Charlas de Mercado

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 may 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 may 2025, 18:51 UTC

Charlas de Mercado

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 may 2025, 18:37 UTC

Charlas de Mercado
Ganancias

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 may 2025, 18:04 UTC

Principales Noticias

S&P 500 Falls After More Trump-China Friction -- WSJ

30 may 2025, 17:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 may 2025, 17:47 UTC

Charlas de Mercado

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 may 2025, 17:40 UTC

Adquisiciones, fusiones, absorciones

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 may 2025, 17:38 UTC

Charlas de Mercado

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 may 2025, 17:31 UTC

Charlas de Mercado

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 may 2025, 17:14 UTC

Principales Noticias

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 may 2025, 16:31 UTC

Ganancias

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 may 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

30 may 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

30 may 2025, 16:16 UTC

Principales Noticias

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 may 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

30 may 2025, 16:14 UTC

Principales Noticias

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Comparación entre iguales

Cambio de precio

Zai Lab Ltd ADR previsión

Precio Objetivo

By TipRanks

109.52% repunte

Estimación a 12 Meses

Media 63.15 USD  109.52%

Máximo 115 USD

Mínimo 32.6 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zai Lab Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

28.13 / 31.12Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

50 / 381 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.